top of page

No-Exam Term Life Insurance With Kidney Failure or Dialysis: What to Expect

Written by: Jeff Schmidt | Licensed Insurance Broker | CarePro Insurance Content reviewed for accuracy. Not legal, tax, or financial advice.

Kidney failure and dialysis are typically outside accelerated/no-exam "instant approval" programs. If coverage is possible, it usually requires specialized underwriting and detailed medical context.

  • Instant online pricing

  • No phone calls required

  • No pressure from agents

Dialysis: Most Instant Tracks Won't Proceed

Cause of kidney failure and overall stability

Dialysis history and related complications

Transplant status and broader health factors

Chronic kidney disease exists on a continuous clinical spectrum, and where an applicant falls on that spectrum has a dramatic and determinative effect on life insurance eligibility. CKD Stage 3 - defined by a glomerular filtration rate (GFR) between 30 and 59 milliliters per minute - represents moderate kidney impairment, but kidney function at this stage is often sufficient for many applicants to qualify for fully underwritten term life coverage, frequently at table ratings that reflect the elevated but manageable risk. Stage 4 CKD (GFR 15-29) presents more significant underwriting challenges and fewer available carriers, while Stage 5 CKD - defined by GFR below 15 or the need for dialysis, also referred to as end-stage renal disease (ESRD) - represents the most restrictive category in the entire renal disease spectrum. Understanding your current CKD stage, with recent laboratory documentation of GFR and creatinine trends, is the foundational first step before beginning any life insurance application, because the stage determines which carriers and products are realistically accessible.

The dialysis modality an applicant uses is a variable that can influence how certain carriers approach the file, though both hemodialysis and peritoneal dialysis ultimately signal ESRD severity that takes the case out of the standard instant underwriting lane. Hemodialysis - typically performed three sessions per week at a dialysis center, each lasting three to four hours - is the more common modality in the United States. Peritoneal dialysis, performed daily by the patient at home using the peritoneal membrane as a filter, is associated in some clinical literature with better preservation of residual kidney function during the early years of dialysis treatment, and some carriers view this slightly more favorably. However, neither modality bypasses the need for full individual underwriting review - any automated or accelerated underwriting platform will decline to process an active dialysis application, and attempting to apply through those channels will produce an automatic result rather than an individualized evaluation.

The underlying cause of kidney failure is a meaningful and independent underwriting variable, not simply a footnote to the renal diagnosis. Diabetic nephropathy - kidney failure driven by long-standing poorly controlled or moderately controlled diabetes mellitus - places two major chronic conditions simultaneously into the underwriting equation, compounding the mortality risk assessment beyond what either diagnosis would represent individually. A case of acute kidney injury, particularly one with a discrete identifiable cause such as a medication reaction or post-surgical complication, that progressed to ESRD without an ongoing systemic disease process presents a different risk narrative - one where the trigger was an event rather than a chronic progressive condition. Polycystic kidney disease, FSGS, IgA nephropathy, and lupus nephritis each carry distinct prognosis patterns that experienced underwriters factor into their carrier-specific guidelines alongside the renal failure diagnosis itself.

Being actively listed for a kidney transplant is significant documentation in the underwriting context, communicating several things simultaneously. Transplant list status formally confirms ESRD severity, since transplant evaluation is initiated only when kidney function has declined to the threshold where organ replacement is the appropriate long-term treatment strategy. It also demonstrates that the transplant program has evaluated the applicant and determined them to be a suitable transplant candidate - which typically requires cardiovascular and general health assessments, implying the applicant has passed an independent medical review. The transplant pathway also opens a potential future coverage window: some carriers are willing to revisit an application after a successful kidney transplant with two to three years of documented stable graft function, normalized creatinine, and well-managed immunosuppression, making a post-transplant application strategy worth planning well in advance.

For applicants currently on dialysis, the realistic expectation must be clearly understood before beginning the search for coverage. Most standard term life carriers will not issue new policies to active dialysis patients, because the five-year survival rate on dialysis - while improving with advances in care - remains substantially lower than the general population, placing most dialysis-dependent applicants outside the mortality thresholds standard carriers underwrite against. However, coverage is not universally unavailable. Simplified issue and guaranteed issue whole life products - which do not require laboratory underwriting or full medical history review in the traditional sense - may offer face amounts typically ranging from $10,000 to $25,000. These products frequently include graded benefit provisions in the first two years of coverage, meaning the full death benefit is not available immediately. Understanding this coverage ceiling clearly before beginning a broad search prevents applicants from spending time pursuing products that are structurally inaccessible to them.

For the general term life overview and how no-exam underwriting works (and when it doesn't), see: https://www.careproinsurance.com/instant-term-life-insurance

The content on this page is informational and educational only; it is not professional advice. Quotes are estimates; eligibility and pricing depend on underwriting and the issued policy.

Frequently Asked Questions

Can I get no-exam term life insurance while on dialysis?

It's difficult and many accelerated/no-exam programs won't proceed. Options, if available, depend on the full medical profile and carrier guidelines. Underwriting applies.

Why do instant programs usually decline kidney failure or dialysis?

Because carriers typically need detailed medical context to evaluate severity and stability, which doesn't fit automated underwriting rules.

Does a kidney transplant change life insurance options?

It can, but it depends on time since transplant, stability, medications, and overall health. Many cases still require full underwriting review.

Will a quote tool show accurate pricing for dialysis cases?

Often not, especially if the tool doesn't ask dialysis-related questions. Underwriting will verify history, and pricing/eligibility can change.

What information should I have ready?

Diagnosis and dialysis start dates, underlying cause, recent stability and hospitalizations, and transplant status can help determine the most realistic path.

I have CKD Stage 3 - am I still able to qualify for term life insurance coverage?

Yes, CKD Stage 3 is meaningfully different from Stage 5 ESRD, and many Stage 3 applicants can qualify for fully underwritten term life coverage. The key factors are your current GFR reading, the rate of GFR decline over time as shown by serial lab work, any comorbid conditions like diabetes or hypertension contributing to the decline, and whether you are under active nephrologist monitoring. Stage 3 applicants who are stable, under specialist care, and without significant progression trends are in a much stronger position than those with rapidly declining function, and many will qualify for coverage at Standard or table-rated levels.

Does it matter to underwriters whether I'm on hemodialysis or peritoneal dialysis?

It can matter at the margin - some carriers view peritoneal dialysis marginally more favorably due to its association with better residual kidney function preservation - but both modalities signal ESRD and require full individual underwriting review. The more determinative factors in any dialysis case are the underlying cause of kidney failure, overall clinical stability, comorbid conditions, time on dialysis, and any transplant evaluation status. Neither modality bypasses the need for full medical underwriting, and no instant-approval platform will process an active dialysis application.

Are there any life insurance products available for someone currently on dialysis?

Standard term life carriers generally will not issue new policies to active dialysis patients, but simplified issue and guaranteed issue whole life products may offer some coverage. These products - which don't require traditional medical underwriting - typically offer face amounts between $10,000 and $25,000, and often include graded benefits meaning the full death benefit may not be payable in the first one to two years. While these aren't equivalent to a traditional term policy, they can provide meaningful coverage for final expenses or small estate needs while an applicant awaits a transplant or other clinical changes that might open additional options.

Get Covered With The Right Plan

Dialysis and end-stage kidney disease often don't fit instant underwriting. This page sets expectations and explains what (limited) next steps may look like.

Explore coverage options

bottom of page